Comparison of surgical outcomes between thoracoscopic anatomical sublobar resection including and excluding subsegmentectomy
Objectives Despite the ubiquitous utilization of anatomical sublobar resection for malignant lung tumors, the effectiveness and feasibility of subsegmentectomy remains unclear. This study therefore compared the perioperative outcomes between anatomical sublobar resection including (IS) and excluding...
Gespeichert in:
Veröffentlicht in: | General thoracic and cardiovascular surgery 2021-05, Vol.69 (5), p.850-858 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Objectives
Despite the ubiquitous utilization of anatomical sublobar resection for malignant lung tumors, the effectiveness and feasibility of subsegmentectomy remains unclear. This study therefore compared the perioperative outcomes between anatomical sublobar resection including (IS) and excluding (ES) subsegmentectomy.
Methods
Patients who had undergone anatomical sublobar resection at our institution from January 2013 to March 2019 were retrospectively reviewed. Clinicopathologic characteristics and perioperative outcomes of the IS group (
n
= 58) were then analyzed the compared to those of the ES group (
n
= 203).
Results
No statistically significant differences in age, sex, comorbidities, tumor location, preoperative pulmonary function, or tumor size on imaging were found between both groups. The IS group had significantly higher preoperative computed tomography-guided marking rates (40% vs. 18%;
p
0.99), intraoperative complications (7% vs. 10%;
p
= 0.61), and postoperative complications (5% vs. 8%;
p
= 0.58). After propensity score matching, the IS group experienced significantly lesser blood loss than the ES group (5 mL, IQR: 1–10 vs. 5 mL, IQR: 5–20;
p
= 0.03). Both groups experienced no local recurrence and demonstrated similar postoperative pulmonary functions after surgery.
Conclusions
IS may be a feasible and acceptable therapeutic option for malignant lung tumors. Nonetheless, future investigations are required to further validate the current findings. |
---|---|
ISSN: | 1863-6705 1863-6713 |
DOI: | 10.1007/s11748-020-01556-3 |